WP6:Preclinical in vivo studies of lead and back-up antibodies

In this workpackage we will :

  • define the optimal anti-SR-BI antibody dose and treatment duration needed to prevent HCV infection and dissemination in mice with a humanised liver

  • evaluate the capacity of the lead anti-HCV antibody to neutralise different HCV genotypes/strains

  • confirm the efficacy of the GMP antibody preparations

  • characterise and evaluate the in vivo efficacy of the back-up antibodies.